Lyme disease: Part II. Management and prevention

Journal of the American Academy of Dermatology

Volumn 64, Issue 4, 2011, Pages 639-653

  Bhate, Chinmoy ^a   Schwartz, Robert A ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

acrodermatitis chronica atrophicans; Borrelia burgdorferi; chronic Lyme disease; erythema migrans; Lyme borreliosis; Lyme disease; lymphocytoma cutis; neuroborreliosis; personal protective behavior; ticks

Indexed keywords

ALPHA2A INTERFERON; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; INSECT REPELLENT; LYME DISEASE VACCINE; MACROLIDE; NUCLEIC ACID; PENICILLIN G; PENICILLIN V; PLACEBO;

ANTIGEN ANTIBODY COMPLEX; BACTERIAL ARTHRITIS; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; DIAGNOSTIC ERROR; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; EHRLICHIOSIS; ENVIRONMENTAL MANAGEMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA ANNULARE CENTRIFUGUM; ERYTHEMA CHRONICUM MIGRANS; ERYTHEMA INFECTIOSUM; ERYTHEMA MULTIFORME; FLUORESCENT ANTIBODY TECHNIQUE; GRANULOMA ANNULARE; HISTOPATHOLOGY; HUMAN; INFECTION CONTROL; LYME DISEASE; NONHUMAN; NUCLEIC ACID ANALYSIS; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RASH; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SINGLE DRUG DOSE; SKIN ALLERGY; TICK BITE; TREATMENT RESPONSE; URTICARIA; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; EDUCATION, MEDICAL, CONTINUING; HUMANS; LYME DISEASE; LYME DISEASE VACCINES;

EID: 79952779730     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.03.047     Document Type: Review

References (171)

1. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease - United States, 1992-2006. MMWR Surveill Summ 2008;57:1-9.
2. Dennis DT, Nekomoto TS, Victor JC, Paul WS, Piesman J. Reported distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the United States. J Med Entomol 1998;35:629-38. (Pubitemid 128463421)
3. Weber K. Aspects of Lyme borreliosis in Europe. Eur J Clin Microbiol Infect Dis 2001;20:6-13. (Pubitemid 32200355)
4. Gray J. Risk assessment in Lyme borreliosis. Wien Klin Wochenschr 1999;111:990-3. (Pubitemid 30026422)
5. Dressler F. Lyme borreliosis in European children and adolescents. Clin Exp Rheumatol 1994;12(suppl 10):S49-54.
6. Masuzawa T. Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis 2004;57:229-35. (Pubitemid 40260237)
7. Hercogová J, Brzonova I. Lyme disease in central Europe. Curr Opin Infect Dis 2001;14:133-7. (Pubitemid 32231098)
8. Hercogová J, Vanousová D. Syphilis and borreliosis during pregnancy. Dermatol Ther 2008;21:205-9.
9. Steere AC. Lyme disease. N Engl J Med 2001;345:115-25. (Pubitemid 32640193)
10. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 1996;335:1270-4. (Pubitemid 26349268)
11. Schutzer SE, Schwartz RA. Diagnosing Lyme disease: often simple, often difficult. Cutis 1991;47:229-30, 32.
12. Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003;348:2472-4. (Pubitemid 36682836)
13. Müllegger RR. Dermatological manifestations of Lyme borreliosis. Eur J Dermatol 2004;14:296-309. (Pubitemid 39222329)
14. Steen CJ, Carbonaro PA, Schwartz RA. Arthropods in dermatology. J Am Acad Dermatol 2004;50:819-42.
15. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011;17:69-79.
16. Tibbles CD, Edlow JA. Does this patient have erythema migrans? JAMA 2007;297:2617-27.
17. Dandache P, Nadelman RB. Erythema migrans. Infect Dis Clin North Am 2008;22:235-60. (Pubitemid 351608545)
18. Aguero-Rosenfeld ME. Lyme disease: laboratory issues. Infect Dis Clin North Am 2008;22:301-13. (Pubitemid 351608538)
19. Schutzer SE, Coyle PK, Dunn JJ, Luft BJ, Brunner M. Early and specific antibody response to OspA in Lyme disease. J Clin Invest 1994;94:454-7. (Pubitemid 24218126)
20. Picken MM, Picken RN, Han D, Cheng Y, Ruzic-Sabljic E, Cimperman J, et al. A two year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. Mol Pathol 1997;50:186-93. (Pubitemid 27454987)
21. Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008;47:188-95. (Pubitemid 351920619)
22. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.
23. Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 2007;49:13-21. (Pubitemid 46160581)
24. Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjoersdorff A, Blanco JR, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004;10:1108-32. (Pubitemid 40050854)
25. Weinstein A. Editorial commentary: laboratory testing for Lyme disease: time for a change? Clin Infect Dis 2008;47:196-7.
26. Belongia EA, Reed KD, Mitchell PD, Chyou PH, Mueller-Rizner N, Finkel MF, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis 1999;29:1472-7. (Pubitemid 30022743)
27. Krause PJ, McKay K, Thompson CA, Sikand VK, Lentz R, Lepore T, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002;34:1184-91.
28. Armstrong PM, Brunet LR, Spielman A, Telford SR III. Risk of Lyme disease: perceptions of residents of a Lone Star tickeinfested community. Bull World Health Organ 2001;79:916-25.
29. Wormser GP, Masters E, Nowakowski J, McKenna D, Holmgren D, Ma K, et al. Prospective clinical evaluation of patients from Missouri and New York with erythema migranselike skin lesions. Clin Infect Dis 2005;41:958-65. (Pubitemid 41368216)
30. Masters EJ, Grigery CN, Masters RW. STARI, or Masters disease: Lone Star tick-evectored Lyme-like illness. Infect Dis Clin North Am 2008;22:361-76. (Pubitemid 351608544)
31. Dana AN. Diagnosis and treatment of tick infestation and tick-borne diseases with cutaneous manifestations. Dermatol Ther 2009;22:293-326.
32. Blanton L, Keith B, Brzezinski W. Southern ticke-associated rash illness: erythema migrans is not always Lyme disease. South Med J 2008;101:759-60.
33. Nowakowski J, Schwartz I, Liveris D, Wang G, Aguero-Rosenfeld ME, Girao G, et al. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis 2001;33:2023-7. (Pubitemid 33152397)
34. Oldak E, Sulik A, Dorota R. The significance of immunoblot tests in diagnosis of Lyme borreliosis in children [in Czech]. Przegl Epidemiol 2008;62(suppl):83-7.
35. Brown SL, Hansen SL, Langone JJ. Role of serology in the diagnosis of Lyme disease. JAMA 1999;282:62-6. (Pubitemid 29318934)
36. Tugwell P, Dennis DT, Weinstein A, Wells G, Shea B, Nichol G, et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997;127:1109-23. (Pubitemid 28012083)
37. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993;269:1812-6. (Pubitemid 23097348)
38. Craft JE, Grodzicki RL, Steere AC. Antibody response in Lyme disease: evaluation of diagnostic tests. J Infect Dis 1984;149:789-95. (Pubitemid 14108384)
39. Magnarelli LA, Meegan JM, Anderson JF, Chappell WA. Comparison of an indirect fluorescent-antibody test with an enzyme-linked immunosorbent assay for serological studies of Lyme disease. J Clin Microbiol 1984;20:181-4. (Pubitemid 15189408)
40. Magnarelli LA. Serologic diagnosis of Lyme disease. Ann N Y Acad Sci 1988;539:154-61.
41. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001;33:780-5. (Pubitemid 32831833)
42. Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest 1986;78:934-9. (Pubitemid 17177073)
43. Bunikis J, Barbour AG. Laboratory testing for suspected Lyme disease. Med Clin North Am 2002;86:311-40. (Pubitemid 34327089)
44. Lencakova D, Fingerle V, Stefancikova A, Schulte-Spechtel U, Petko B, Schreter I, et al. Evaluation of recombinant line immunoblot for detection of Lyme disease in Slovakia: comparison with two other immunoassays. Vector Borne Zoonotic Dis 2008;8:381-90. (Pubitemid 351860466)
45. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of lyme borreliosis. Clin Microbiol Rev 2005;18:484-509. (Pubitemid 40995113)
46. Marangoni A, Moroni A, Accardo S, Cevenini R. Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 2008;27:349-54.
47. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD Jr, Philipp MT, Steere AC, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003;187:1187-99. (Pubitemid 36438958)
48. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993;167:392-400. (Pubitemid 23036442)
49. Bakken LL, Case KL, Callister SM, Bourdeau NJ, Schell RF. Performance of 45 laboratories participating in a proficiency testing program for Lyme disease serology. JAMA 1992;268:891-5.
50. Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Bryant SC, Beito EM. Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots. J Clin Microbiol 2008;46:2216-21.
51. Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 1995;33:419-27.
52. Schutzer SE, Coyle PK, Belman AL, Golightly MG, Drulle J. Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease. Lancet 1990;335:312-5. (Pubitemid 20051260)
53. Schutzer SE, Coyle PK, Reid P, Holland B. Borrelia burgdorferie specific immune complexes in acute Lyme disease. JAMA 1999;282:1942-6.
54. Schutzer SE, Luan J. Early OspA immune complex formation in animal models of Lyme disease. J Mol Microbiol Biotechnol 2003;5:167-71. (Pubitemid 37475746)
55. Schutzer SE, Janniger CK, Schwartz RA. Lyme disease during pregnancy. Cutis 1991;47:267-8.
56. Marques AR, Hornung RL, Dally L, Philipp MT. Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi. Clin Diagn Lab Immunol 2005;12:1036-40. (Pubitemid 41324533)
57. Wilske B, Schierz G, Preac-Mursic V, von Busch K, Kuhbeck R, Pfister HW, et al. Intrathecal production of specific antibodies against Borrelia burgdorferi in patients with lymphocytic meningoradiculitis (Bannwarth's syndrome). J Infect Dis 1986;153:304-14. (Pubitemid 16156065)
58. Hansen K, Cruz M, Link H. Oligoclonal Borrelia burgdorferie specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 1990;161:1194-202. (Pubitemid 20177880)
59. Hansen K, Lebech AM. Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferie-specific immunoglobulin G, A, and M. Ann Neurol 1991;30:197-205.
60. Baig S, Olsson T, Hansen K, Link H. Anti- Borrelia burgdorferi antibody response over the course of Lyme neuroborreliosis. Infect Immun 1991;59:1050-6.
61. Magnarelli LA, Miller JN, Anderson JF, Riviere GR. Crossreactivity of nonspecific treponemal antibody in serologic tests for Lyme disease. J Clin Microbiol 1990;28:1276-9. (Pubitemid 20194417)
62. Bruckbauer HR, Preac-Mursic V, Fuchs R, Wilske B. Crossreactive proteins of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1992;11:224-32.
63. Lahdenne P, Panelius J, Saxen H, Heikkilä T, Sillanpää H, Peltomaa M, et al. Improved serodiagnosis of erythema migrans using novel recombinant borrelial BBK32 antigens. J Med Microbiol 2003;52:563-7. (Pubitemid 36871894)
64. Heikkilä T, Huppertz HI, Seppälä I, Sillanpää H, Saxen H, Lahdenne P. Recombinant or peptide antigens in the serology of Lyme arthritis in children. J Infect Dis 2003;187:1888-94. (Pubitemid 36724487)
65. Dattwyler RJ. A commentary on the treatment of early lyme disease. Clin Infect Dis 2010;50:521-2.
66. Berger BW, Johnson RC, Kodner C, Coleman L. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992;30:359-61.
67. van Dam AP, Kuiper H, Vos K, Widjojokusumo A, de Jongh BM, Spanjaard L, et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 1993;17:708-17. (Pubitemid 23293384)
68. Wormser GP, Bittker S, Cooper D, Nowakowski J, Nadelman RB, Pavia C. Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease. J Clin Microbiol 2000;38:1648-50. (Pubitemid 30216706)
69. Pachner AR, Zhang WF, Schaefer H, Schaefer S, O'Neill T. Detection of active infection in nonhuman primates with Lyme neuroborreliosis: comparison of PCR, culture, and a bioassay. J Clin Microbiol 1998;36:3243-7. (Pubitemid 28476173)
70. Zanconati F, Cattonar P, Grandi G. Histochemical and immunohistochemical methods for demonstration of spirochetes in skin biopsies. Acta Derm Venereol (Ljubljana) 1994;3:99-104. (Pubitemid 24248931)
71. Hödl S, Soyer H, Müllegger R. Dermatopathologic diagnosis of Lyme borreliosis. Acta Derm Venereol (Ljubljana) 1996;5:123-9. (Pubitemid 27048889)
72. Chodynicka B, Schwartz RA, Flisiak I. Acrodermatitis chronica atrophicans. Available at: http://emedicine.medscape.com/article/1051695- overview. Accessed June 20, 2009.
73. Weger W, Müllegger RR. Histopathology and immunohistochemistry of dermatoborreliosis. Acta Derm Venereol (Ljubljana) 2001;10:135-42.
74. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994;330:229-34. (Pubitemid 24034134)
75. Tang YW, Hibbs JR, Tau KR, Qian Q, Skarhus HA, Smith TF, et al. Effective use of polymerase chain reaction for diagnosis of central nervous system infections. Clin Infect Dis 1999;29:803-6. (Pubitemid 30256372)
76. Pícha D, Moravcová L, Holecková D, Zd'árský E, Valesová M, Maresová V, et al. Examination of specific DNA by PCR in patients with different forms of Lyme borreliosis. Int J Dermatol 2008;47:1004-10.
77. Schmidt BL. PCR in laboratory diagnosis of human Borrelia burgdorferi infections. Clin Microbiol Rev 1997;10:185-201. (Pubitemid 27042836)
78. Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, et al. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol 1992;30:3082-8.
79. Lebech AM, Hansen K. Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J Clin Microbiol 1992;30:1646-53.
80. Lange R, Seyyedi S. Evidence of a Lyme borreliosis infection from the viewpoint of laboratory medicine. Int J Med Microbiol 2002;291(suppl 33):120-4. (Pubitemid 34775972)
81. Figueroa R, Bracero LA, Aguero-Rosenfeld M, Beneck D, Coleman J, Schwartz I. Confirmation of Borrelia burgdorferi spirochetes by polymerase chain reaction in placentas of women with reactive serology for Lyme antibodies. Gynecol Obstet Invest 1996;41:240-3. (Pubitemid 26168182)
82. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983;99:22-6. (Pubitemid 13066652)
83. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990;336:1404-6.
84. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000;31(suppl 1):1-14.
85. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134. (Pubitemid 44637131)
86. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117:273-80.
87. Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995;39:661-7.
88. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992;36:1788-90.
89. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996;124:785-91.
90. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002;109:1173-7. (Pubitemid 34587449)
91. Müllegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children-a prospective study. Infection 1991;19:279-83.
92. Kaiser R. Neuroborreliosis. J Neurol 1998;245:247-55.
93. Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 1989;46:1190-4. (Pubitemid 19268386)
94. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sörgel F, Einhäupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991;163:311-8.
95. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994;44:1203-7. (Pubitemid 24232215)
96. Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. Scand J Infect Dis 2001;33:259-62. (Pubitemid 32366649)
97. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, noninferiority, double-blind, randomised trial. Lancet Neurol 2008;7:690-5.
98. Thorstrand C, Belfrage E, Bennet R, Malmborg P, Eriksson M. Successful treatment of neuroborreliosis with ten day regimens. Pediatr Infect Dis J 2002;21:1142-5. (Pubitemid 35463031)
99. Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005;117:393-7. (Pubitemid 41158819)
100. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991;34:1056-60.
101. Przytula L, Gindzienska-Sieskiewicz E, Sierakowski S. Diagnosis and treatment of Lyme arthritis [in Czech]. Przegl Epidemiol 2006;60(suppl 1):125-30.
102. Puechal X. Nonantibiotic treatments of Lyme borreliosis [in Spanish]. Med Mal Infect 2007;37:473-8. (Pubitemid 47362544)
103. Strle F, Maraspin V, Pleterski-Rigler D, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, et al. Treatment of borrelial lymphocytoma. Infection 1996;24:80-4. (Pubitemid 26062748)
104. Müllegger RR, Glatz M. Skin manifestations of lyme borreliosis: diagnosis and management. Am J Clin Dermatol 2008;9:355-68.
105. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Picken RN, et al. Solitary borrelial lymphocytoma in adult patients. Wien Klin Wochenschr 2002;114:515-23. (Pubitemid 34847335)
106. Vanousová D, Hercogová J. Lyme borreliosis treatment. Dermatol Ther 2008;21:101-9. (Pubitemid 351499213)
107. Aydogan K, Karadogan SK, Adim SB, Tunali S. Borrelial lymphocytoma cutis successfully treated with intralesional interferon-alpha-2A. J Eur Acad Dermatol Venereol 2006;20:1030-2.
108. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Asbrink E. Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment. Acta Neurol Scand 2002;106:253-7. (Pubitemid 35177991)
109. Leslie TA, Levell NJ, Cutler SJ, Cann KJ, Smith ME, Wright DJ, et al. Acrodermatitis chronica atrophicans: a case report and review of the literature. Br J Dermatol 1994;131:687-93. (Pubitemid 24344057)
110. Aberer E, Breier F, Stanek G, Schmidt B. Success and failure in the treatment of acrodermatitis chronica atrophicans. Infection 1996;24:85-7. (Pubitemid 26062749)
111. Flisiak I, Chodynicka B, Laudanska H, Reduta T, Stefanska-Sulik E, Pucilo K, et al. Study on clinical picture of erythema migrans. Rocz Akad Med Bialymst 1996;41:78-82.
112. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis 2002;2:255-63.
113. Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, et al. A critical appraisal of "chronic Lyme disease.". N Engl J Med 2007;357:1422-30.
114. Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am 2008;22:341-60. (Pubitemid 351608543)
115. Stricker RB, Johnson L. Chronic Lyme disease and the 'Axis of Evil.'. Future Microbiol 2008;3:621-4.
116. Moniuszko A, Czupryna P, Zajkowska J, Pancewicz SA, Grygorczuk S, Kondrusik M. Post Lyme syndrome as a clinical problem [in Polish]. Pol Merkur Lekarski 2009;26:227-30.
117. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med 2010;123:79-86.
118. Hsu VM, Patella SJ, Sigal LH. "Chronic Lyme disease" as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum 1993;36:1493-500.
119. Cameron D, Gaito A, Harris N, Bach G, Bellovin S, Bock K, et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004;2:S1-13.
120. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with lyme disease. Clin Infect Dis 2007;45:149-57. (Pubitemid 47041004)
121. Auwaerter PG. Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to lyme disease. Clin Infect Dis 2007;45:143-8. (Pubitemid 47041003)
122. Holden S. Ticked off. New York Times. Available at: http://movies. nytimes.com/2009/06/19/movies/19under.html. Accessed September 25, 2009.
123. Holmes KD. An appraisal of "chronic Lyme disease.". N Engl J Med 2008;358:429, reply 30-1.
124. Maloney EL. An appraisal of "chronic Lyme disease.". N Engl J Med 2008;358:428-9, reply 30-1.
125. Volkman DJ. An appraisal of "chronic Lyme disease.". N Engl J Med 2008;358:429, reply 30-1.
126. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92. (Pubitemid 32634566)
127. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003;60:1923-30. (Pubitemid 36736007)
128. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003;60:1916-22.
129. Ronn S. In the Lymelight: law and clinical practice guidelines. South Med J 2009, May 7: [epub ahead of print].
130. Cameron DJ. Insufficient evidence to deny antibiotic treatment to chronic Lyme disease patients. Med Hypotheses 2009;72:688-91.
131. Cameron DJ. Clinical trials validate the severity of persistent Lyme disease symptoms. Med Hypotheses 2009;72:153-6.
132. Schutzer SE, Brown T Jr, Holland BK. Reduction of Lyme disease exposure by recognition and avoidance of high-risk areas. Lancet 1997;349:1668. (Pubitemid 27234812)
133. Schutzer SE, Holland BK, Brown T Jr. Avoidance of tick-borne diseases. Ann Intern Med 1998;128:784.
134. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003;348:2424-30.
135. Katz TM, Miller JH, Hebert AA. Insect repellents: historical perspectives and new developments. J Am Acad Dermatol 2008;58:865-71.
136. Brown M, Hebert AA. Insect repellents: an overview. J Am Acad Dermatol 1997;36:243-9. (Pubitemid 27078920)
137. Rozendaal JA. Vector control: methods for use by individuals and communities. Geneva: World Health Organization; 1997.
138. Del Fabbro S, Nazzi F. Repellent effect of sweet basil compounds on Ixodes ricinus ticks. Exp Appl Acarol 2008;45:219-28.
139. Zhang A, Klun JA, Wang S, Carroll JF, Debboun M. Isolongifolenone: a novel sesquiterpene repellent of ticks and mosquitoes. J Med Entomol 2009;46:100-6.
140. Cantrell CL, Klun JA, Pridgeon J, Becnel J, Green S III, Fronczek FR. Structure-activity relationship studies on the mosquito toxicity and biting deterrency of callicarpenal derivatives. Chem Biodivers 2009;6:447-58.
141. Bissinger BW, Apperson CS, Sonenshine DE, Watson DW, Roe RM. Efficacy of the new repellent BioUD against three species of ixodid ticks. Exp Appl Acarol 2009;48:239-50.
142. Vazquez M, Muehlenbein C, Cartter M, Hayes EB, Ertel S, Shapiro ED. Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis 2008;14:210-6.
143. Gould LH, Nelson RS, Griffith KS, Hayes EB, Piesman J, Mead PS, et al. Knowledge, attitudes, and behaviors regarding Lyme disease prevention among Connecticut residents, 1999-2004. Vector Borne Zoonotic Dis 2008;8:769-76.
144. Orloski KA, Campbell GL, Genese CA, Beckley JW, Schriefer ME, Spitalny KC, et al. Emergence of Lyme disease in Hunterdon County, New Jersey, 1993: a case-control study of risk factors and evaluation of reporting patterns. Am J Epidemiol 1998;147:391-7.
145. Piesman J. Strategies for reducing the risk of Lyme borreliosis in North America. Int J Med Microbiol 2006;296(Suppl. 40):17-22. (Pubitemid 43668593)
146. Stafford KC III, Ward JS, Magnarelli LA. Impact of controlled burns on the abundance of Ixodes scapularis (Acari: Ixodidae). J Med Entomol 1998;35:510-3. (Pubitemid 128460083)
147. Schulze TL, Jordan RA, Hung RW. Suppression of subadult Ixodes scapularis (Acari: Ixodidae) following removal of leaf litter. J Med Entomol 1995;32:730-3.
148. Stafford KC III, Denicola AJ, Kilpatrick HJ. Reduced abundance of Ixodes scapularis (Acari: Ixodidae) and the tick parasitoid Ixodiphagus hookeri (Hymenoptera: Encyrtidae) with reduction of white-tailed deer. J Med Entomol 2003;40:642-52. (Pubitemid 37399536)
149. Rand PW, Lubelczyk C, Holman MS, Lacombe EH, Smith RP Jr. Abundance of Ixodes scapularis (Acari: Ixodidae) after the complete removal of deer from an isolated offshore island, endemic for Lyme disease. J Med Entomol 2004;41:779-84. (Pubitemid 38991518)
150. Húgli D, Moret J, Rais O, Moosmann Y, Erard P, Malinverni R, et al. Tick bites in a Lyme borreliosis highly endemic area in Switzerland. Int J Med Microbiol 2008.
151. Falco RC, Fish D, Piesman J. Duration of tick bites in a Lyme disease-endemic area. Am J Epidemiol 1996;143:187-92. (Pubitemid 26036260)
152. Centers for Disease Control and Prevention: Division of Vector Borne Infectious Diseases. Lyme disease: tick removal. Available at: http://www.cdc.gov/ncidod/dvbid/Lyme/ld-tickremoval.htm. Accessed July 18, 2009.
153. Piesman J, Dolan MC. Protection against lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 2002;39:509-12. (Pubitemid 135700286)
154. Miyamoto K, Hashimoto Y. Prevention of Lyme borreliosis infection after tick bites [in Japanese]. Kansenshogaku Zasshi 1998;72:512-6.
155. Pitches DW. Removal of ticks: a review of the literature. Euro Surveill 2006;11:E060817.4.
156. De Boer R, van den Bogaard AE. Removal of attached nymphs and adults of Ixodes ricinus (Acari: Ixodidae). J Med Entomol 1993;30:748-52.
157. Needham GR. Evaluation of five popular methods for tick removal. Pediatrics 1985;75:997-1002. (Pubitemid 15036511)
158. Lanschuetzer CM, Wieser M, Laimer M, Emberger M, Hintner H. Improving the removal of intact ticks. Australas J Dermatol 2003;44:301.
159. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345:79-84. (Pubitemid 32634565)
160. Stanek G, Strle F. Lyme borreliosis. Lancet 2003;362:1639-47. (Pubitemid 37443533)
161. Leenders AC. Single-dose doxycycline for the prevention of Lyme disease. N Engl J Med 2001;345:1349, reply 50.
162. Bellovin SM. Single-dose doxycycline for the prevention of Lyme disease. N Engl J Med 2001;345:1349, reply 50.
163. Hunfeld KP, Brade V. Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know. Wien Klin Wochenschr 2006;118:659-68. (Pubitemid 44953968)
164. Livey I, Dorner F. Development of an OspC vaccine against Lyme borreliosis. Acta Derm Venereol (Ljubljana) 1996;5:185-8. (Pubitemid 27048900)
165. Meurice F, Parenti D, Fu D, Krause DS. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. Clin Infect Dis 1997;25(Suppl. 1):S71-5.
166. Rutter T. Lyme disease vaccine given guarded approval in the US. BMJ 1998;316:1695.
167. Schutzer SE, Luan J, Coyle PK. Detection of Lyme disease after OspA vaccine. N Engl J Med 1997;337:794-5. (Pubitemid 27417988)
168. Van Hoecke C, Fu D, De Grave D, Voet P, Lebacq E. Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12. Vaccine 1998;16:1688-92. (Pubitemid 28366083)
169. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999;5:321-8. (Pubitemid 29289445)
170. Lathrop SL, Ball R, Haber P, Mootrey GT, Braun MM, Shadomy SV, et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002;20:1603-8.
171. Earnhart CG, Marconi RT. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccin 2007;3:281-9.